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Abstract
Background: There is limited data on the epidemiology of influenza and few published estimates of influenza vaccine
effectiveness (VE) from Africa. In April 2009, a new influenza virus strain infecting humans was identified and rapidly spread
globally. We compared the characteristics of patients ill with influenza A(H1N1)pdm09 virus to those ill with seasonal
influenza and estimated influenza vaccine effectiveness during five influenza seasons (2005–2009) in South Africa.
Methods: Epidemiological data and throat and/or nasal swabs were collected from patients with influenza-like illness (ILI) at
sentinel sites. Samples were tested for seasonal influenza viruses using culture, haemagglutination inhibition tests and/or
polymerase chain reaction (PCR) and for influenza A(H1N1)pdm09 by real-time PCR. For the vaccine effectiveness (VE)
analysis we considered patients testing positive for influenza A and/or B as cases and those testing negative for influenza as
controls. Age-adjusted VE was calculated as 1-odds ratio for influenza in vaccinated and non-vaccinated individuals.
Results: From 2005 through 2009 we identified 3,717 influenza case-patients. The median age was significantly lower
among patients infected with influenza A(H1N1)pdm09 virus than those with seasonal influenza, 17 and 27 years
respectively (p,0.001). The vaccine coverage during the influenza season ranged from 3.4% in 2009 to 5.1% in 2006 and
was higher in the $50 years (range 6.9% in 2008 to 13.2% in 2006) than in the ,50 years age group (range 2.2% in 2007 to
3.7% in 2006). The age-adjusted VE estimates for seasonal influenza were 48.6% (4.9%, 73.2%); 214.2% (29.7%, 34.8%);
12.0% (270.4%, 55.4%); 67.4% (12.4%, 90.3%) and 29.6% (221.5%, 60.1%) from 2005 to 2009 respectively. For the
A(H1N1)pdm09 season, the efficacy of seasonal vaccine was 26.4% (293.5%, 43.3%).
Conclusion: Influenza vaccine demonstrated a significant protective effect in two of the five years evaluated. Low vaccine
coverage may have reduced power to estimate vaccine effectiveness.
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Introduction
Influenza is an acute viral infection characterized by rapid
spread, regular winter epidemics in temperate countries and year-
round circulation in the tropical regions [1–2]. It is highly
infectious and associated with significant morbidity and mortality
in high-risk individuals worldwide [3]. In South Africa, influenza
and pneumonia were the second leading cause of death during the
years 2005 to 2009 [4–8].
The global influenza surveillance network of the World Health
Organization (WHO) serves as a mechanism to monitor the
influenza types and subtypes circulating globally as well as an alert
mechanism for the emergence of novel influenza viruses with
potential to cause pandemics [9]. In April 2009, a new influenza
virus strain infecting humans was detected in the United States
and Mexico and by 15 July had spread to more than 100 countries
including South Africa [10–11].
Vaccination is the primary public health measure for preventing
influenza infection [3]. However, circulating influenza viruses
constantly change requiring an annual update of influenza
vaccines to match the current circulating strains [12]. Twice
yearly, the WHO recommends the content of the influenza
vaccine for the forthcoming influenza season [9]. These recom-
mendations are based on data submitted by its global influenza
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surveillance network [9]. In South Africa, influenza vaccination is
provided at no charge at public health facilities for people who are
at risk of severe disease (persons aged .65 years, those with
underlying conditions, pregnant women, residents of rehabilitation
institutions, children on long-term aspirin therapy, healthcare
workers responsible for the care of high risk cases, family contacts
of high-risk cases) and is available at a fee in the private sector
[13]. During 2011–2013 influenza seasons, vaccine coverage
among people aged .65 years and pregnant women were
reported to be 2% and 14% respectively (Ramkrishna W et al –
Options for the Control of Influenza VIII).
Prior to 2006, there was limited surveillance for influenza and
little was known about the epidemiology of influenza on the
continent. However progress has been made in recent years [2,14–
15]. Nevertheless, there are still limited data on the uptake of
influenza vaccines and their effectiveness on the African continent.
Several studies in other parts of the world have shown the
feasibility of estimating vaccine effectiveness (VE) from surveil-
lance data [16–17]. We analysed influenza-like illness (ILI)
surveillance data to compare the epidemiological characteristics
of patients infected with influenza A(H1N1)pdm09 virus to those
infected with seasonal influenza. In addition we estimated
influenza vaccine effectiveness (VE) from the national ILI
surveillance network during five influenza seasons (2005–2009)
and assessed whether the 2009 seasonal influenza vaccine had a
protective effect against the A(H1N1)pdm09 influenza virus in the
same year. During the period of our study only seasonal influenza
vaccine was available and there was no pandemic vaccine
available.
Methods
Ethics Statement
The NICD has ethics clearance for essential communicable
disease surveillance activities of public health importance in South
Africa granted by the Human Medical Research Ethics Commit-
tee of the University of the Witwatersrand, Johannesburg. Our
study was conducted using surveillance data that fall into the
specification mentioned above. None of the authors participated in
sample collection. Samples were given a unique identifier before
analysis. If requested our data will be made available upon
publication.
Study Design and Setting
The Viral Watch in South Africa is a prospective influenza
surveillance programme based on a network of sentinel general
practitioners who report on ILI cases seen in their practices [18]. It
is coordinated by the National Institute for Communicable
Diseases (NICD) of the National Health Laboratory Service
(NHLS). The programme encompasses mainly (approximately
90%) private primary health care centers and some public facilities
situated in all nine provinces of South Africa and is conducted
throughout the year [18]. It is estimated that 16% of individuals in
South Africa seek care in the private sector [19]. In 2005 the
sentinel sites were situated only in Gauteng Province. From 2006
the surveillance programme progressively expanded to reach
coverage in all nine provinces in 2008 [18]. During the study
period (2005–2009), demographic characteristics, date of illness
onset and sample collection, signs and symptoms (data on
underlying condition were not available), and influenza vaccina-
tion history were collected using standard data collection forms
from patients who presented with ILI defined as sudden onset of
fever (temperature of $38uC) with at least two of the following
symptoms: cough, headache, myalgia or sore throat. Sample
collection was recommended to be within three days of onset of
symptoms; however a small proportion (10%) of specimens
collected .3 days after onset were also received [18]. An ILI
case was defined as influenza positive when laboratory results
positive for influenza A and/or B viruses were obtained. In 2009,
because of the increased demand for laboratory testing with the
advent of influenza A(H1N1)pdm09 in South Africa, sentinel sites
were requested to limit the number of enrolled cases to a
maximum of five per week. In the previous years there was no
limitation on enrollment of cases.
Sample Collection and Laboratory Testing
Throat and/or nasal swabs were collected from all enrolled
patients and transported (on ice) to the laboratory in viral
transport medium (VTM) for influenza virus detection. Specimens
from seven of the nine provinces were tested at the National
Influenza Centre (NIC) situated at the NICD-NHLS, while
specimens from two other provinces (KwaZulu-Natal and Western
Cape) were tested at their respective laboratories and positive
samples sent to the NICD-NHLS for subtyping and sequencing.
From 2005–2007, typing was performed mainly by haemaggluti-
nation inhibition (HAI) test while in 2008 about 50% could not be
typed by HAI hence PCR was used. In 2009, due to the emerging
pandemic strain, the more sensitive United States Centers for
Disease Control and Prevention polymerase chain reaction (PCR)
was used for the detection and characterization of the influenza
A(H1N1)pdm09 virus. Few HAI tests were performed in 2009.
Data Management and Analysis
The detection rate (number of influenza positive specimens/
number of specimens submitted) was calculated only for those
specimens tested at the NICD during the influenza season as we
received very low numbers during the influenza off-season
(although clinicians are requested to submit specimens throughout
the year) which can lead to falsely high detection rates.
For the VE analysis, patients were considered vaccinated if they
received influenza vaccine $2 weeks before onset of symptoms
and unvaccinated if they were not vaccinated for that season or
received influenza vaccine ,2 weeks before symptoms onset.
Patients without reported vaccination status or vaccination date
were classified as unknown and were excluded from the VE
analysis. We restricted the VE analysis to patients who presented
at Viral Watch sentinel sites from seven of the nine provinces
within the influenza season. We did not have denominators of
specimens tested in the other two provinces as a result they were
excluded from the VE analysis.
The start and the end of the influenza season were defined as a
weekly detection rate of $10% and ,10% for two consecutive
weeks respectively. In 2009 two distinct waves of influenza
circulation were observed, the first was dominated by influenza
A(H3N2) and the second by influenza A(H1N1)pdm09. There was
a two week overlap between the two waves, as a result specimens
collected during this period were classified in both seasons.
However, patients who tested positive for A(H1N1)pdm09 virus
(n = 161) during the 2009 seasonal influenza were considered as
negative for seasonal influenza while those who tested positive for
seasonal influenza viruses (n = 129) during the A(H1N1)pdm09
virus circulation were considered as negative for A(H1N1)pdm09
virus in the VE analysis.
We considered patients with ILI and positive for influenza A
and/or B viruses as cases and patients with ILI, but laboratory-
negative for influenza as controls [20–21]. Age-adjusted (,50 and
$50 years) VE was calculated as 1-odds ratio (OR) for influenza in
vaccinated and non-vaccinated individuals. Significance was
Influenza Vaccine Effectiveness in South Africa
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assessed at p,0.05 for all analysis. Data were analyzed using
OpenEpi version 2.3 (US Centers for Disease Control and
Prevention, Atlanta, Georgia, United States).
Results
Influenza Virus Detection and Seasonality
From 2005 through 2009, a total of 8,559 specimens were
received at the NICD for the detection of respiratory viruses from
Viral Watch sentinel sites. Of these, 3,205 (37%) tested positive for
influenza A and/or B viruses. In addition another 512 positive
specimens were received from KwaZulu-Natal and Western Cape
provinces, bringing the total influenza positives to 3,717 (ranging
from 388 influenza positives in 2008 to 1,714 in 2009– Figure 1).
Of those, 3,248 (87%) were influenza A, 458 (12%) influenza B
and 11 (0.3%) tested positive for both A and B influenza viruses.
Of the 11 patients with both A and B influenza viruses identified,
three were excluded from the analysis as both pandemic and
seasonal influenza viruses were detected. The other eight mixed
infections were classified as seasonal as the A influenza virus
identified was the seasonal one. Among the influenza A viruses,
3,075 (95%) were further subtyped; 1,597 (52%) were A(H3N2),
776 (25%) were A(H1N1) and 702 (23%) were A(H1N1)pdm09
virus. The annual detection rate amongst specimens tested at
NICD during the influenza seasons ranged from 32% in 2008 to
47% in 2005 and 2007 (Figure 1).
The median age was significantly lower among patients infected
with influenza A(H1N1)pdm09 virus (17, range: 0–97 years) than
those infected with seasonal influenza viruses (A(H1N1), A(H3N2)
and B), (27, 0–84years) (p,0.001). However, the highest detection
rate was among the 5–24 years age group for both pandemic and
seasonal influenza cases (Figure 2). The age distribution of
influenza A(H1N1)pdm09 case-patients was similar to those
infected with influenza B but differed from that of patients with
seasonal influenza A subtypes A(H1N1) and A(H3N2) (Figure 3).
The median age for influenza A(H1N1)pdm09 and seasonal
influenza B patients was 17 (range 0–97) and 18 (range 0–78) years
respectively while those for seasonal A(H1N1) and A(H3N2) was
28 (range 0–73) and 29 (range 0–84) years respectively.
Predominant A subtypes differed by year. Influenza A(H1N1)
was predominant during the years 2005 (317/564, 56%) and 2008
(308/388, 79%) while A(H3N2) was predominant during 2006
(417/541, 77%) and 2007 (208/510, 41%). From 2005 through
2008, influenza epidemics were unimodal and occurred predom-
inantly from June to August. The duration of the seasonal
influenza period ranged from 11 weeks in 2009 to 19 weeks in
2005. In 2009 two distinct waves of influenza circulation were
observed: the first occurred in May to July and was dominated by
influenza A(H3N2) virus and lasted for 11 weeks, while the second
occurred in July to September and was dominated by influenza
A(H1N1)pdm09 virus and lasted for a period of eight weeks
(Figure 4).
Vaccine Effectiveness
From 2005 through 2009 during the influenza season, a total of
7,535 ILI patients from seven of the nine provinces were enrolled
as follows: 5,946 (79%) during five seasonal influenza seasons and
1,589 (21%) during the A(H1N1)pdm09 circulation period in
2009. Of the patients enrolled during the seasonal influenza season
and the A(H1N1)pdm09 circulation period 95% (5,649/5,946)
and 97% (1,541/1,589) met the ILI WHO case definition of fever
$38uC and cough or sore throat, respectively. Two percent (140/
5,946) and 6% (93/1,589) of cases during the seasonal and
pandemic influenza period respectively were excluded from the
VE analysis because of their unknown vaccination status. In 2009
influenza A(H3N2) (n = 129) and A(H1N1)pdm09 (n= 161) co-
circulated for a period of two weeks.
Seasonal influenza. Of the 5,806 patients enrolled during
the pre-2009 pandemic influenza seasons and with known
vaccination status, 2,502 (43%) tested positive for influenza A
and/or B viruses and 234 (4%) received influenza vaccine. The
overall vaccine coverage during the pre-2009 pandemic influenza
seasons was 4.0% (range 3.4% in 2009 to 5.1% in 2006 (Table 1)
and was higher in the $50 years (range 6.9% in 2008 to 13.2% in
2006) than in the ,50 years (range 2.2% in 2007 to 3.7% in 2006)
age groups in all five influenza seasons. The influenza detection
rate ranged from 31.9% in 2008 to 46.7% in 2005 and was higher
in the ,50 years (range 32.8% in 2008 to 47.4% in 2005) than in
Figure 1. Number of specimens testing positive for influenza and detection rates by year, Viral Watch, South Africa, 2005–2009.
doi:10.1371/journal.pone.0094681.g001
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the $50 years (range 25.0% in 2008 to 44.6% in 2006) in four
(2005–2008) of the five influenza seasons (Figure 5).
The age-adjusted VE estimates ranged from 214.2% (95% CI:
299.7% to 34.8%) in 2006 to 67.4% in 2008 (95% CI: 12.4% to
90.3%) (Table 1). Influenza vaccination demonstrated a significant
protective effect during the 2005 (VE: 48.6%, 95%CI: 4.9 to 73.2)
and 2008 (VE: 67.4%, 95%CI: 12.4 to 90.3) seasonal influenza
seasons (Table 1). Stratifying by age, there was no significant
difference between the two age groups except in 2005 where a
higher VE of 73% (95% CI: 36.2 to 90.1) was noted in those aged
,50 than in the $50 age group (VE: 229.3%, 95% CI: 2245.3
to 52.1).
The vaccine composition and the influenza types circulating in
South Africa from 2005–2009 are provided in Table 1.
Influenza A(H1N1)pdm09. Of the 1,589 patients with ILI
enrolled, 496 (31%) tested positive for influenza A(H1N1)pdm09
virus. Vaccination status was known for 1,496 (94%) patients. Of
these, 54 (3.6%) received seasonal influenza vaccine. Vaccine
coverage was higher in those aged$50 (8.6%, 12/140) than in the
,50 (3.1%, 42/1,356) age group. The detection rate was higher in
those aged ,50 (33%, 446/1356) than in the $50 (13%, 18/140)
Figure 2. Influenza detections and detection rates for seasonal influenza (N=2490) and influenza A(H1N1)pdm09 (N=496) by age
group, Viral Watch, South Africa: 2005–2009.
doi:10.1371/journal.pone.0094681.g002
Figure 3. Percentage of influenza positives by age group and virus type, Viral Watch, South Africa; 2005–2009.
doi:10.1371/journal.pone.0094681.g003
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years age group. The age-adjusted VE estimate was 26.4% (95%
CI: 293.5% to 43.3%) (Table 2).
Discussion
This article is among the first to describe influenza vaccine
effectiveness on the African Continent. We demonstrated influen-
za vaccine effectiveness against seasonal influenza in two (2005
and 2008) of the five years surveyed where the seasonal A (H1N1)
Figure 4. Number of influenza positives by virus type, subtype and detection rate by week and year, Viral Watch, South Africa,
2005–2009.
doi:10.1371/journal.pone.0094681.g004
Table 1. Comparison of vaccine composition to circulating viruses, South Africa, 2005–2009.
Year Vaccine composition Circulating viruses
2005 A/New Caledonia/20/99(H1N1)-like virus A/New Caledonia/20/99(H1N1)-like virus
A/Wellington/1/2004(H3N2)-like virus A/California/7/2004(H3N2)-like virus
B/Shanghai/361/2002-like virus B/Hong Kong/333/01-like virus
2006 A/New Caledonia/20/99(H1N1)-like virus A/New Caledonia/20/99(H1N1)-like virus
A/California/7/2004(H3N2)-like virus A/Wisconsin/67/2005(H3N2)-like virus
B/Malaysia/2506/2004-like virus B/Malaysia/2506/2004-like virus
2007 A/New Caledonia/20/99(H1N1)-like virus A/Solomon Islands/3/2006 (H1N1)-like virus
A/Wisconsin/67/2005(H3N2)-like virus A/Brisbane/10/2007 (H3N2)-like virus
B/Malaysia/2506/2004-like virus B/Malaysia/2506/2004-like virus
2008 A/Solomon Islands/3/2006 (H1N1)-like virus A/Brisbane/59/2007 (H1N1)-like virus
A/Brisbane/10/2007 (H3N2)-like virus A/Brisbane/10/2007 (H3N2)-like virus
B/Florida/4/2006-like virus B/Florida/4/2006-like virus
2009 A/Brisbane/59/2007 (H1N1)-like virus A/California/7/2009 (H1N1)-like virus
A/Brisbane/10/2007 (H3N2)-like virus A/Perth/16/2009 (H3N2)-like virus
B/Florida/4/2006-like virus B/Brisbane like-virus
Predominating circulating strains in bold.
Predominating B strains indicated.
doi:10.1371/journal.pone.0094681.t001
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subtype was dominant. However, we did not demonstrate
significant VE during the years when the H3N2 subtype was
dominant. This is similar to what was reported in other settings
when a strain mismatch of the A(H3N2) vaccine component was
identified [17,22]. In 2006 and 2007 there was a mismatch
between the H3N2 vaccine composition strains and circulating
viruses. The molecular characterization of representative influenza
A (H3N2) isolates circulating in South Africa showed an extensive
genetic drift from the vaccine component strains A/California/7/
04 (H3N2)–like virus, A/Wisconsin/67/05 (H3N2)-like virus
respectively [23–24]. In 2006 the circulating influenza A (H3N2)
viruses were related to the A/Wisconsin/67/05 (H3N2)-like virus
while in 2007 were related to the A/Brisbane/10/07 (H3N2)–like
virus respectively [23–24]. In 2009, the majority of the H3N2
isolates were characterized by antigenic distances of $3.25 when
compared to the vaccine component strain (Unpublished data –
Treurnicht F et al In prep). Nonetheless, several studies have
shown that influenza vaccines can afford cross-protection against
non-matching circulating strains [25].
In addition, as expected, there was no significant protective
effect of the seasonal influenza vaccine against the influenza
A(H1N1)pdm09 virus strain. This finding has been reported in
other countries and settings [26]. It is known that vaccine efficacy
depends on the match between the vaccine composition and the
circulating strain [3]. In 2009, a new influenza virus strain
emerged, making communities vulnerable to influenza as this
strain was not included in the Southern hemisphere 2009 seasonal
influenza vaccine. When adjusting for age, VE estimates
decreased; similar findings have been reported in other settings
[17,22]. While vaccination with seasonal influenza vaccines may
induce some increase in antibody response to pandemic virus in
adults aged ,60 years, increases are not observed in older
individuals [27–28]. This is likely as a result of preexisting cross-
reactive antibodies in this age group. It has also been suggested
Figure 5. The vaccine coverage and detection rate during influenza by year and age group, Viral Watch, South Africa, 2005–2009.
doi:10.1371/journal.pone.0094681.g005
Table 2. Vaccination coverage* and vaccine effectiveness by year, Viral Watch, South Africa: 2005–2009.
Year, season Vaccination coverage
Overall Cases % (n/N) Controls % (n/N) Crude VE (95% CI)
Age-adjusted VE
(95% CI)
Seasonal influenza
2005 4.1 (49/1199) 2.7 (15/558) 5.3 (34/641) 50.9 (9.8, 74.2) 48.6 (4.9, 73.2)
2006 5.1 (54/1055) 5.5 (26/476) 4.8 (28/579) 213.1 (296.5, 35.9) 214.2 (299.7, 34.8)
2007 4.2 (40/957) 3.6 (16/446) 4.7 (24/511) 24.5 (243.9, 61.2) 12.0 (270.4, 55.4)
2008 3.7 (32/858) 1.5 (4/261) 4.7 (28/597) 68.3 (15.1, 90.6) 67.4 (12.4, 90.3)
2009 3.4 (59/1737) 2.8 (20/716) 3.8 (39/1021) 27.6 (224.2, 58.9) 29.6 (221.5, 60.1)
A(H1N1)pdm09
2009 3.6 (54/1496) 3.4 (16/464) 3.7 (38/1 032) 6.6 (267.6, 49.7) 26.4 (293.5, 43.3)
Statistically significant values in bold.
*The proportion of individuals who received at least one dose of influenza vaccine in the relevant period.
Age groups: ,50 and $50 years.
doi:10.1371/journal.pone.0094681.t002
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that seasonal influenza infection may protect against infection with
the pandemic strain [29].
Although influenza is a vaccine-preventable disease, the uptake
of influenza vaccine in developing countries is poor. Even in
industrialized countries, large proportions of high risk groups do
not receive influenza vaccine [30]. In South Africa, influenza
vaccine coverage among ILI patients seen at Viral Watch sentinel
sites, which includes mainly private general practitioners, was very
low (average 4%) in all five influenza seasons. While coverage was
generally higher amongst the elderly, it remained below 10%.
Unfortunately as data on high risk groups were not available,
coverage in these important risk populations could not be assessed.
Challenges in acquiring data on the epidemiology and burden of
influenza continue. However, advances had been made in
understanding the epidemiology, burden and seasonality of
influenza as illustrated by surveillance activities being done in
the continent [2,15,31]. Efforts to increase and maintain high
vaccination coverage should be emphasized especially to groups at
high risk for severe and complicated disease.
There was a significant difference in the age distribution of case-
patients between those with pandemic and seasonal influenza.
Patients infected with A(H1N1)pdm09 virus were younger than
those with seasonal influenza. This is similar to what has been
described in other settings [32–34]. In our study older children
and young adults aged 5–24 years comprised 68% of patients
infected with A(H1N1)pdm09 virus (only one was aged .65
years). This might be as a result of some residual protective
immunity among older adults from past exposures to the A H1N1
virus as well as potential bias in specimen collection [35–36].
In South Africa, influenza epidemics were experienced from
May to September and peaked during winter months (June –
August) in all five pre-pandemic influenza seasons. This is
expected as South Africa experiences a temperate climate.
However, in 2009, South Africa experienced two apparent
influenza peaks, the first corresponding to the expected annual
seasonal influenza season followed by a second and distinct wave
that was dominated by influenza A(H1N1)pdm09 and extended to
the spring months. This is in contrast to what has been
experienced in other temperate southern hemisphere countries,
where only one influenza peak predominated by A(H1N1)pdm09
virus was observed [37].
Our study has several limitations. First, we could not assess the
severity of cases or influenza-related mortality as the Viral Watch
system surveys only outpatients with ILI. Second, data presented
here relate only to patients who presented with ILI at sentinel sites
from whom specimens were taken, it is not representative of all
influenza infections in South Africa. However, it does provide
information on the epidemiology of ILI in seasonal and pandemic
influenza years which may be of value to the health care system.
Third, vaccination status was determined from data collection
forms as reported by practitioner; we did not verify these reports
ourselves. Fourth, in the VE analysis we could not control for
potential confounders such as underlying medical conditions as
these data were not available for the years surveyed. We did
control for differences in age distribution, which has been shown
to be the most important potential confounder of vaccine
effectiveness estimates, however due to limitations in numbers of
cases we were only able to stratify by two age bands [16,38]. Fifth,
due to low vaccine coverage and low case numbers in some years
we may have been under-powered to determine low and subtype-
specific VE. Lastly, since the HAI is less sensitive than the PCR we
may have some false negatives in some years resulting in some
cases being included as controls. This may have some effect on the
VE estimate, probably overestimating VE during the years 2005–
2007 when mainly HAI was used for the identification of
influenza.
In conclusion, this longstanding influenza surveillance pro-
gramme was able to monitor the circulation of seasonal and
pandemic influenza when it occurred in the country and allowed
for the estimation of annual VE. Efforts should be made to
increase vaccination coverage and improve the data collection
tools (e.g. including the collection of information on underlying
medical conditions and other possible confounders) to allow for
proper adjustment of VE estimates. Feedback to clinicians on
vaccine effectiveness will encourage them to participate in the
influenza surveillance programme as well as to vaccinate. In
addition, vaccine effectiveness data may be useful to countries in
the Northern hemisphere if similar strains circulate in their
upcoming influenza season.
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